Drugs / TAK-285
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00535522 | Aug 2007 → Jun 2011 | cancer | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-285 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00535522 ↗ |
| Action | Inhibit | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL1614725 ↗1“inhibitor of EGFR and HER2” PMID 23817974 ↗ Jul 2013 |
| Modality | Small molecule | — CHEMBL1614725 ↗ |
| Route | Oral | “received daily oral TAK-285” PMID 23817974 ↗ Jul 2013 |
| Target | EGFR | “inhibitor of EGFR and HER2” PMID 23817974 ↗ Jul 2013 |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL1614725 ↗ |